Posted by Michael Wonder on 01 Aug 2024
FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy
1 August 2024 - Today, the FDA approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer.
Efficacy was evaluated in RUBY, a randomised, multi-centre, double-blind, placebo-controlled trial conducted in 494 patients with primary advanced or recurrent endometrial cancer.
